Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CNSX:BUX NYSE:CRL NYSEARCA:SIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBUXBiomark Diagnostics$0.00$0.00▼$0.00N/AN/AN/A11,500 shsCRLCharles River Laboratories International$159.78-2.4%$144.87$91.86▼$254.15$8.04B1.491.03 million shs518,978 shsSILGlobal X Silver Miners ETF$50.84+3.5%$45.47$28.02▼$51.04$2.06B0.981.23 million shs3.17 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBUXBiomark Diagnostics0.00%0.00%0.00%0.00%0.00%CRLCharles River Laboratories International-2.36%+1.69%+5.80%+60.49%-21.18%SILGlobal X Silver Miners ETF+3.52%+3.56%+6.03%+26.40%+47.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International4.5497 of 5 stars2.15.00.04.72.92.51.9SILGlobal X Silver Miners ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBUXBiomark Diagnostics 0.00N/AN/AN/ACRLCharles River Laboratories International 2.25Hold$174.549.24% UpsideSILGlobal X Silver Miners ETF 2.66Moderate Buy$50.84N/ACurrent Analyst Ratings BreakdownLatest SIL, BUX, BD1, and CRL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$170.00 ➝ $180.007/9/2025CRLCharles River Laboratories InternationalCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$150.00 ➝ $200.005/23/2025CRLCharles River Laboratories InternationalRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$188.00 ➝ $182.005/14/2025CRLCharles River Laboratories InternationalCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy5/14/2025CRLCharles River Laboratories InternationalTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$179.005/8/2025CRLCharles River Laboratories InternationalBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$145.00 ➝ $155.005/8/2025CRLCharles River Laboratories InternationalRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$118.00 ➝ $140.005/8/2025CRLCharles River Laboratories InternationalEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeIn-Line ➝ Outperform$170.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBUXBiomark DiagnosticsN/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$4.05B1.94$21.19 per share7.54$67.80 per share2.36SILGlobal X Silver Miners ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBUXBiomark DiagnosticsN/AN/A0.00N/AN/AN/AN/AN/AN/ACRLCharles River Laboratories International$22.20M-$0.65N/A14.535.54-0.66%15.19%6.93%8/6/2025 (Estimated)SILGlobal X Silver Miners ETFN/AN/A32.07∞N/AN/AN/AN/AN/ALatest SIL, BUX, BD1, and CRL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025CRLCharles River Laboratories International$2.50N/AN/AN/A$983.76 millionN/A5/7/2025Q1 2025CRLCharles River Laboratories International$2.06$2.34+$0.28$0.50$942.34 million$984.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBUXBiomark DiagnosticsN/AN/AN/AN/AN/ACRLCharles River Laboratories InternationalN/AN/AN/AN/AN/ASILGlobal X Silver Miners ETF$0.831.63%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBUXBiomark DiagnosticsN/AN/AN/ACRLCharles River Laboratories International0.781.431.16SILGlobal X Silver Miners ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBUXBiomark DiagnosticsN/ACRLCharles River Laboratories International98.91%SILGlobal X Silver Miners ETFN/AInsider OwnershipCompanyInsider OwnershipBUXBiomark DiagnosticsN/ACRLCharles River Laboratories International1.30%SILGlobal X Silver Miners ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBUXBiomark DiagnosticsN/AN/AN/ANot OptionableCRLCharles River Laboratories International20,10049.12 million48.48 millionOptionableSILGlobal X Silver Miners ETFN/A42.56 millionN/ANot OptionableSIL, BUX, BD1, and CRL HeadlinesRecent News About These CompaniesSilver rallies above $38 in ‘incredible breakout' to 13-year highsJuly 11 at 12:31 PM | kitco.comKGold price up, silver soars to 13-year highJuly 11 at 9:06 AM | kitco.comKSilver investment ramps up, 2025 ETF inflows already surpass all of 2024 – Silver InstituteJuly 10 at 12:04 PM | kitco.comKGold, silver see price gains as risk appetite slipsJuly 10 at 8:46 AM | kitco.comKGold, silver, and platinum are all poised for further gains in H2 2025 – Saxo's HansenJuly 9 at 12:02 PM | kitco.comKSilver Miners ETF (SIL) Hits New 52-Week HighJuly 8, 2025 | zacks.comGold, silver weaker but up from session lowsJuly 7, 2025 | kitco.comKCentral banks go for gold, investors still see value in silver, platinum may consolidate after rapid price rise – HeraeusJuly 7, 2025 | kitco.comKShould I Buy Precious Metal ETFs, or Gold and Silver Directly?July 7, 2025 | 247wallst.comGold and silver prices poised for further gains amid mounting economic risks - Sprott's McIntyreJuly 2, 2025 | kitco.comKGold, silver gain as U.S. jobs report on deckJuly 2, 2025 | kitco.comKSilver struggles at $36, but Natixis remains bullish on upside potentialJune 30, 2025 | kitco.comKSilver and platinum rallies could falter in Q3, gold loses ground on renewed risk appetite – HeraeusJune 30, 2025 | kitco.comKGold And Silver Prices Keep Going VerticalJune 27, 2025 | 247wallst.comGold, silver firmer as risk appetite fades a bitJune 25, 2025 | kitco.comKSilver and platinum investment surges as hawkish Fed, flagging safe haven bid saps gold – HeraeusJune 23, 2025 | kitco.comKGold, silver gain on safe-have bids, technical buyingJune 23, 2025 | kitco.comKPrice pressure on gold, silver on profit takingJune 20, 2025 | kitco.comKSurging Silver Prices Prompt Americans to Empty Jewelry Boxes and Coin JarsJune 19, 2025 | wsj.comIndustrial Demand Creating Momentum for SilverJune 18, 2025 | etftrends.comEETFs With the Best Returns of 2025: Gold and Silver Miners on Top (SIL)...April 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesMore Than a Monetary Metal: Silver's Case for OutperformanceBy Jeffrey Neal Johnson | June 22, 2025View More Than a Monetary Metal: Silver's Case for OutperformanceTop 3 Silver Picks to Watch as Bull Market Gains SteamBy Chris Markoch | June 18, 2025View Top 3 Silver Picks to Watch as Bull Market Gains SteamThe Other AI Chipmaker: Why Marvell's Dip Is a BuyBy Jeffrey Neal Johnson | June 12, 2025View The Other AI Chipmaker: Why Marvell's Dip Is a BuyOverheated Market? Analysts Watch These Red FlagsBy Chris Markoch | June 20, 2025View Overheated Market? Analysts Watch These Red FlagsEnovix Shares Hit 6-Month High; Long-Term Highs to FollowBy Thomas Hughes | July 10, 2025View Enovix Shares Hit 6-Month High; Long-Term Highs to FollowSIL, BUX, BD1, and CRL Company DescriptionsBiomark Diagnostics CNSX:BUXBioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.Charles River Laboratories International NYSE:CRL$159.78 -3.88 (-2.37%) Closing price 07/11/2025 03:58 PM EasternExtended Trading$159.44 -0.33 (-0.21%) As of 07/11/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Global X Silver Miners ETF NYSEARCA:SIL$50.84 +1.73 (+3.52%) As of 07/11/2025 04:10 PM EasternThe Global X Silver Miners ETF (SIL) is an exchange-traded fund that mostly invests in materials equity. The fund tracks a market-cap-weighted index of companies actively engaged in the silver mining industry. SIL was launched on Apr 19, 2010 and is managed by Global X. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
